Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccineBNT162b2 mRNA 백신 2회 접종 후 발열 강도 및 해열제 사용과 특이 항체 반응의 관계Article Published on 2022-03-182022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acquisition Adverse reaction Adverse reactions age Analysis analyzed antibody Antibody Response Antipyretic antipyretics association BNT162b2 mRNA vaccine body temperature collected correlated COVID-19 COVID-19 vaccine degree dose female Fever FIVE healthcare worker highest hospital IgG IgG titer IgG titers intensity interfere investigated medication mitigate Multivariate analysis of BNT162b2 participant positive correlation questionnaire reactogenicity reactogenicity event relation reported responses SARS-CoV-2 second dose serum sample Sex significantly spike-specific IgG the SARS-CoV-2 Vaccine was measured [DOI] 10.1016/j.vaccine.2022.02.025 PMC 바로가기 [Article Type] Article
COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland폴란드 교사에게 투여된 ChAdOx1 백신의 반응성 및 면역원성의 맥락에서 COVID-19 백신 접종Article Published on 2022-03-062022-09-10 Journal: International Journal of Environmental Research an [Category] MERS, SARS, 진단, 치료기술, [키워드] adverse effects Adverse reaction Adverse reactions age All participant All participants anti-RBD Anti-RBD IgG Antibody Response ChAdOx1 ChAdOx1 vaccine ChAdOx1-S chills Context COVID-19 demonstrated detectable determinants dose dosing interval Efficacy ENhance female first dose headache immunogenicity immunologic response immunologic responses individual Infection interval malaise male mRNA multivariate logistic regression offered Older participant Participants Poland predictor RBD reactogenicity Receptor-binding domain Region reported required SARS-CoV-2 SARS-COV-2 infection Serological testing Side effect Side effects Support teacher teachers the mean the median the receptor-binding domain Tolerability uninfected Vaccine were measured [DOI] 10.3390/ijerph19053111 PMC 바로가기 [Article Type] Article
Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccinationReview Article Published on 2022-03-022022-10-04 Journal: NPJ Vaccines [Category] 임상, [키워드] Affect alleviate analgesics available data change changes in clinical trial contribute COVID-19 vaccine Diseases dose effective Efficacy Evidence Healthcare professional immune response immunology management medication pandemic parameter prophylactically public health reactogenicity recipient recommendation remains uncertain Side effects Specific Still Symptom unlikely vaccination Vaccine vaccine immunogenicity Vaccine-induced immunity Vaccines were used with COVID-19 [DOI] 10.1038/s41541-022-00453-5 PMC 바로가기 [Article Type] Review Article
Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects기능적 B 세포 결함이 있는 원발성 면역결핍 환자에서 코로나19 메신저 RNA 백신의 면역원성과 내약성Multicenter Study Published on 2022-03-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] MERS, SARS, 진단, 치료기술, [키워드] ACE2 ACE2 blocking antibody ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody Antibody deficiency Antibody Response Antibody responses B-cell blocking activity blocking antibody BNT162b2 BNT162b2 vaccine cellular immunity Clinical management cohort of patient common variable immunodeficiency coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine trials detectable dose effective Efficacy enzyme evaluated functional Good Good syndrome help humoral Humoral response humoral responses IFN-γ IgG antibody IgG responses immune responses immunodeficiency immunogenicity information less mAb Messenger RNA Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 neutralization not effective Patient patients Pfizer-BioNTech PID PIDs positive Primary immunodeficiencies Primary Immunodeficiency RBD RBD binding RBD-specific IgG responses Reactions reactogenicity Receptor binding domain referred to respiratory retrospective retrospective review Safe SARS-CoV-2 SARS-CoV-2 IFN-γ release assay SARS-CoV-2 spike protein SARS-CoV-2 spike protein antibody SARS-CoV-2 spike protein receptor binding domain SARS-CoV-2 vaccination severe acute respiratory syndrome Coronavirus Spike protein spike protein RBD stimulated subject subjects T-cell immune response T-cell Response the spike protein Tolerability vaccination Vaccine was performed were excluded with COVID-19 [DOI] 10.1016/j.jaci.2021.11.022 PMC 바로가기 [Article Type] Multicenter Study
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine코로나19 백신을 이용한 이종 프라임-부스트 면역의 반응원성과 면역원성Review Published on 2022-03-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] SARS, 변종, 임상, [키워드] adverse events bioRxiv Cellular immune response Characteristics clinical trial clinical trials Cochrane Library COVID-19 COVID-19 vaccination database delta variant evaluated Evidence Final Heterologous heterologous prime-boost heterologous prime-boost immunization heterologous vaccination regimen heterologous vaccination regimens humoral immune response immunogenic immunogenicity Inactivated vaccine instrument medRxiv mRNA mRNA-based vaccine New observational studies outcome pandemic Prime-boost provided reactogenicity regimen risk Risk of bias robust searched selected Support systemic reactions Systemic review tolerable vaccination Vaccine vaccine administration variant with COVID-19 [DOI] 10.1016/j.biopha.2022.112650 PMC 바로가기 [Article Type] Review
Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis유지 투석을 받는 환자에서 상동 mRNA 기반 및 벡터 기반 SARS-CoV-2 백신 요법의 면역원성과 반응성Article Published on 2022-03-012022-09-12 Journal: Clinical immunology (Orlando, Fla.) [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Anti-spike IgG antibody assays benefit cellular Cellular immune response cellular immunity CMIA Complete conducted COVID-19 dialysis dose ELISPOT Hemodialysis homologous humoral immune response Humoral immunity immune immune response immunization immunoassay immunogenicity immunoglobulins interferon-γ Microparticle morbidity and mortality mRNA-based Patient Peritoneal dialysis predict reactogenicity receiving regimen SARS-CoV-2 vaccine seroconversion rate single dose single-center study T cell T cells the patient vaccine injection while [DOI] 10.1016/j.clim.2022.108961 PMC 바로가기 [Article Type] Article
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452IgG-Fc 융합 COVID-19 서브유닛 백신 AKS-452에 대한 I/II상 연구의 I상 중간 결과Clinical Trial Published on 2022-02-232022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 AKS-452 Alpha alpha and delta variants anti-SARS-CoV-2 Antigen caused Cell Cohort cohorts cold chain complex conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta variants distribution dose Endpoint Fc-fusion fusion protein healthy human IgG1 Fc IgG titer IgG titers immunogenicity assessments Infection Infectious disease Live virus mutant neutralization potency occurred Open-label pandemic phase Phase I primary endpoints profile Prophylaxis reactogenicity receiving Receptor binding domain respiratory SAE SAEs SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 viral infection secondary endpoint Secondary endpoints seroconversion rates severe acute respiratory syndrome Coronavirus single-center Single-dose skewed Spike protein subject subunit Subunit vaccine Support the SARS-CoV-2 vaccination Vaccine Viral viral infections viral spike protein virus infection [DOI] 10.1016/j.vaccine.2022.01.043 PMC 바로가기 [Article Type] Clinical Trial
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery systemClinical Trial Published on 2022-02-232023-06-24 Journal: Vaccine [Category] 신종인플루엔자, [키워드] adjuvant hemagglutination inhibition antibody immunogenicity influenza vaccine reactogenicity [DOI] 10.1016/j.vaccine.2022.01.034 [Article Type] Clinical Trial
Revival of the heterologous prime‐boost technique in COVID ‐19: An outlook from the history of outbreaksVaccines Published on 2022-02-232022-11-01 Journal: Health Science Reports [Category] COVID-19, [키워드] addition Appendix approach article Canada carried clinical study ClinicalTrials competency Controlled Controlled trial country COVID COVID‐19 COVID‐19 vaccines Critical database Ebola Ebola virus disease English language Evolution expected Germany globe help hepatitis B Heterologous heterologous prime‐boost technique HIV homologous immune response immunization include Influenza virus majority malaria material Mix and Match approach omicron outbreak Outbreaks positive Primary outcomes public health reactogenicity recipients regimen reported Result retrieved risk SARS‐CoV‐2 Spread Tuberculosis turn United Kingdom vaccinate vaccination Vaccine variant WHO [DOI] 10.1002/hsr2.531 PMC 바로가기 [Article Type] Vaccines
SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 diseaseSARS-CoV-2 BNT162b2 백신 유도 체액 반응 및 이전 COVID-19 질병이 있는 개인의 반응성Clinical Medicine Published on 2022-02-222022-09-12 Journal: JCI Insight [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accelerated Adaptive immunity antibody binding domain BNT162b2 BNT162b2 vaccine controls COVID-19 COVID-19 disease COVID-19 group dose Fever first dose greater headache Health care humoral humoral immune response Humoral response humoral responses Hypothesis IgG antibody immune immune responses individual individuals injection malaise manifested MOST mRNA vaccine Neutralizing Neutralizing activity no increase of BNT162b2 peak Pfizer protective immune response rapid increase reactogenicity Reinfection response robust SARS-CoV-2 SARS-CoV-2 BNT162b2 second dose serum serum IgG spike IgG spike receptor-binding domain supported systemic reactions Temple University tested Vaccine vaccine dose were assessed [DOI] 10.1172/jci.insight.155889 PMC 바로가기 [Article Type] Clinical Medicine